Gonadotropin hormone

HCG

Per the Novarel label, HCG action is "virtually identical to that of pituitary LH, although HCG appears to have a small degree of FSH activity as well".1 The app lists a 29 hour half-life; one study measured 2.32 days.2

Strong evidenceGet the app

Level after one dose

HCG after one dose: 50% at ~29 h, 25% at 58 h, 12.5% at 87 h.

Drawn from the half-life in the app's model, ~29 h. The model's figures

1

How Milligram users log it

Track your protocol with Milligram.

4%The 15th most tracked compound in Milligram: of people who track compounds in Milligram logged HCG in the last 90 days.

Schedule

  1. Daily4%
  2. Every other day46%
  3. Twice a week38%
  4. Weekly11%
  5. Less often1%
Among people with three or more logged doses, by the average gap between their doses.

Logged doses

Half of people logged between 250 and 500 IU per dose; the median was 250 IU.

Each person's usual logged amount. The bar starts at zero; the shaded part is the middle half, the mark the median.

Tracked alongside

The share of people logging HCG who also logged each.

From dose logs in the Milligram app, 90 days to 15 November 2026. Aggregated and anonymous. This describes what people recorded, not what anyone should take.

Human chorionic gonadotropin (HCG) is, in the words of the Novarel label, "a polypeptide hormone produced by the human placenta", composed of an alpha and a beta subunit.1 Novarel (Ferring) is derived from human pregnancy urine and given intramuscularly after reconstitution, and the Pregnyl label (Organon) describes a product obtained from the urine of pregnant persons.1,3 Recombinant hCG (choriogonadotropin alfa, sold as Ovidrel) is a separate product, whose label describes activities "comparable to those of placental and human pregnancy urine-derived hCG".4

The Novarel label lists three uses: prepubertal cryptorchidism not due to anatomic obstruction, selected cases of hypogonadotropic hypogonadism in males, and induction of ovulation and pregnancy in an anovulatory, infertile woman who has been appropriately pretreated with human menotropins.1 The app files HCG under post-cycle therapy, but that list does not mention use alongside testosterone or anabolic androgens.

The app grades the evidence for HCG as strong; that grade is the app's own.

3

How it works

Sources in this part

  1. 1Ferring Pharmaceuticals, 2023

Per the Novarel label, HCG "stimulates production of gonadal steroid hormones by stimulating the interstitial cells (Leydig cells) of the testis to produce androgens and the corpus luteum of the ovary to produce progesterone".1

4

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~29 h
Bioavailability
45%
Typical dose
250–1500 IU
Route
SubQ / IM
Time to peak
~12 h

The app lists a half-life of about 29 hours for HCG. Damewood and colleagues (Fertility and Sterility, 1989) measured serum HCG after intramuscular injection (dose not given in the record) in 34 patients undergoing ovarian stimulation in an in vitro fertilization programme and report that the disappearance rate measured 36 hours after injection "was exponential with a mean half-life of 2.32 days".2

The Ovidrel label, which describes recombinant hCG (250 µg) given subcutaneously to women, reports a mean terminal half-life of "about 29 ± 6 hours", a maximum serum concentration "after approximately 12 to 24 hours" and absolute bioavailability of "about 40%" in healthy female volunteers.4 That half-life matches the app's 29 hours, while the bioavailability (against the app's 45%) and the time to peak (median 24 hours, range 12 to 24, against the app's 12 hours) differ; the Novarel and Pregnyl labels carry no such figures for urinary HCG.4

Table 4.1Half-life and pharmacokinetics5 rows
ParameterApp's figureReported in the sources
Half-lifeAbout 29 hoursMean 2.32 days, measured from 36 hours after intramuscular HCG in 34 patients in an IVF programme; about 29 ± 6 hours for subcutaneous recombinant hCG in women (Ovidrel label)2,4
Bioavailability45%No figure in the Novarel and Pregnyl labels or in the PubMed records of the Damewood, Saal and Shah studies; about 40% for subcutaneous recombinant hCG in women (Ovidrel label)4
Time to peakAbout 12 hoursSubcutaneous recombinant hCG in women: median 24 hours (range 12 to 24); in men, peak concentration was "significantly delayed" after subcutaneous compared with intramuscular HCG4,7
Duration of activityAbout 72 hoursNo duration figure; serum HCG was detectable up to 14 days after injection in one study2
RouteSubcutaneous or intramuscularNovarel and Pregnyl labels: intramuscular use only; Ovidrel label: subcutaneous use1,3,4

Saal and colleagues (Fertility and Sterility, 1991) randomised 24 healthy male volunteers, mean age 22.7 ± 4.3 years, to a single 5,000 IU injection of HCG intramuscularly or subcutaneously.7 They report that peak concentration "was significantly delayed (P = 0.01) and serum half-life was prolonged (P = 0.01) after SC injection; however, T, LH, and FSH responses were identical".7

Shah and colleagues (Journal of Clinical Endocrinology and Metabolism, 2014) gave 22 women (body mass index 18.5 to 24.9 or 30 to 40 kg/m2) intramuscular urinary hCG and, after a 4-week washout, subcutaneous recombinant hCG, so route and product differ.8 Peak, area under the curve and average concentration were higher after intramuscular than after subcutaneous injection in both groups (all P < .003), and obese women had "markedly lower" values after subcutaneous injection than normal-weight women (P = .02, .009 and .008).8

The chart draws a one-compartment model with the app's half-life of 29 hours and time to peak of 12 hours, using intervals that a label or study reports. With the 2.32 day half-life measured by Damewood and colleagues, the curve would fall more slowly.2

Level over 1 weeks

Interval between doses

Level, as a share of the peak after one 500 IU dose

As studied: every other day5, twice a week1, once a week6. As logged in Milligram: the share of people with three or more logged doses on each schedule (How Milligram users log it).

An illustration from a pharmacokinetic model using a half-life of 29 hours. It is not a measured level or a suggested dose.

5

Human studies

Table 5.1Human studies7 rows
Study and yearDesignPeopleDose and lengthMain result
Rajfer and colleagues, New England Journal of Medicine, 19869Randomised, double-blind comparison of parenteral HCG with intranasal gonadotropin-releasing hormone (GnRH)933 boys aged 1 to 5 (29 unilateral, 4 bilateral cryptorchidism)9HCG 3300 IU per week for 4 weeks; GnRH 1.2 mg per day for 28 days9Descent in 1 of 17 boys given HCG (6%) and 3 of 16 given GnRH (19%; P = 0.23); testosterone rose in both groups, with higher levels in the HCG group (P < 0.05); descent in all 5 boys with retractile testes given HCG in a parallel uncontrolled study. The authors call either hormone "in most cases, ineffective" for true cryptorchid testes.9
Lijesen and colleagues, British Journal of Clinical Pharmacology, 199510Criteria-based meta-analysis of published trials of HCG in obesity1024 trials (8 controlled, 16 uncontrolled); participant numbers not given in the record10Not applicable: trials scored for method quality10Of the 12 studies scoring 50 or more points, one reported that HCG was a useful adjunct. The authors conclude "there is no scientific evidence that HCG is effective in the treatment of obesity".10
Coviello and colleagues, Journal of Clinical Endocrinology and Metabolism, 20055Randomised; four groups (saline placebo or three HCG doses), all given testosterone enanthate529 men with normal reproductive physiology5200 mg testosterone enanthate weekly plus placebo or 125, 250 or 500 IU HCG every other day, 3 weeks5Intratesticular testosterone (ITT) fell 94% (1234 to 72 nmol/liter) with placebo. After treatment ITT was 25% below baseline with 125 IU, 7% below with 250 IU and 26% above with 500 IU, and rose linearly with dose (P < 0.001).5
Hsieh and colleagues, The Journal of Urology, 201311Retrospective review of records, before-and-during comparison1126 hypogonadal men, mean age 35.9 years (19 on injectable testosterone, 7 on gel)11Testosterone (daily gel or weekly injection) plus 500 IU HCG intramuscularly every other day; mean follow-up 6.2 months11No patient became azoospermic, semen parameters did not differ over more than 1 year of follow-up, and 9 of 26 men contributed to a pregnancy. Mean serum testosterone was 207.2 before and 1,055.5 ng/dl during treatment (p <0.0001).11
Wenker and colleagues, The Journal of Sexual Medicine, 201512Retrospective case series from two tertiary care infertility clinics, with no comparison group in the record; the authors call it "an early report" and describe improved tolerability and speed of recovery as "presumed"1249 men with azoospermia or severe oligospermia (<1 million sperm/mL) while taking exogenous testosterone123,000 units HCG subcutaneously every other day with clomiphene citrate, tamoxifen, anastrozole or recombinant FSH (or a combination)12Return of spermatogenesis or improved counts in 47 men (95.9%), mean 4.6 months to return; no significant difference by testosterone type or supplemental therapy. Panken and Halpern describe these men as "managed with androgen cessation and hCG therapy".12,15
Smit and colleagues, Fertility and Sterility Reports, 202513Retrospective analysis of clinic records, no control group, harm reduction clinic in the Netherlands1319 men using non-prescribed androgens for at least 3 months, mean age 33; 15 azoospermic at first analysis13Recombinant HCG, mean 2,273 IU per week; second analysis after a median of 17 weeks; men advised to move to 125 to 150 mg of a testosterone ester per week13Mean total sperm count rose from 18.0 to 146.9 million (P=.008) and total motile sperm count from 1.1 to 66.8 million (P=.011); 11 men (58%) reached a normal motile count, 6 stayed oligozoospermic and 2 azoospermic.13
Muir and colleagues, Clinical Endocrinology, 202514Systematic review and meta-analysis1441 studies, 1673 men with pathologic gonadotropin deficiency, mean age 25 (± 5) years14Gonadotropin treatment (hCG alone or hCG with FSH), median 18 months14Mean sperm concentration 11.6 M/mL (95% CI 8.4 to 14.9); sperm output and the share reaching every threshold were significantly greater with hCG/FSH than with hCG monotherapy.14

Deeper analysis: Coviello and colleagues, Journal of Clinical Endocrinology and Metabolism, 2005

Coviello and colleagues randomised 29 men with normal reproductive physiology to 200 mg testosterone enanthate weekly with saline placebo or with 125, 250 or 500 IU HCG every other day for 3 weeks, and took testicular fluid by percutaneous fine needle aspiration at baseline and at the end of treatment.5 Baseline serum testosterone (14.1 nmol/liter) was 1.2% of ITT (1174 nmol/liter), and LH and FSH were "profoundly suppressed to 5% and 3% of baseline, respectively" (the record does not state in which group).5 The authors conclude that "relatively low dose hCG maintains ITT within the normal range in healthy men with gonadotropin suppression".5 They state that "the quantitative relationship between ITT and spermatogenesis is not known", and the record gives no sperm results.5

Deeper analysis: Smit and colleagues, Fertility and Sterility Reports, 2025

The 19 men had used androgens without a break for a mean of 43 months.13 The HCG was typically Ovitrelle, a recombinant product, in injections of 520 to 1,040 IU three times a week, and besides HCG the men "were advised to stop the use of high-dose androgen cycles and transition to a maintenance dose of 125–150 mg of a testosterone ester".13 Total sperm count and total motile sperm count improved in 16 (84%) and 17 (89%) of the 19 men, no factor tested, including the weekly HCG dose, was a significant predictor of change (P>.05), and six pregnancies were reported among the men.13 The authors list as limitations that the study "is retrospective in nature and lacked randomization and a control group", that there was no follow-up sperm analysis, that varicocele and testicular size were not analysed and sperm morphology was not an outcome (they cite Karila and colleagues, 2004, who found a higher hCG dose associated with more morphologically abnormal sperm), and that the small single-clinic sample "further limit the generalizability".13 They add that all men "continued a maintenance dose of testosterone while using hCG, leaving it unclear whether similar results would be observed in men undergoing high-dose androgen cycles".13 Their declaration of interests reports "funding from Doping Authority Netherlands and Spaarne Gasthuis Academy for the submitted work".13 The report gives no adverse event results.13 In a commentary, Panken and Halpern note that "the investigators did not include any data on symptoms or serum testosterone level measurements before or during the treatment period" and that the follow-up was short.15

Deeper analysis: Lijesen and colleagues, British Journal of Clinical Pharmacology, 1995

Lijesen and colleagues traced published trials of HCG in obesity "by computer-aided search and citation tracking" and scored each for method quality.10 Scores ran from 16 to 73 points out of 100, "suggesting that most studies were of poor methodological quality", and the 12 studies scoring 50 or more points were all controlled.10

6

Doses reported in studies and labels

The app lists a typical dose of 250 to 1500 IU. The table gives the doses the labels and studies report, each for the people and schedule shown, in the units each source uses. The labels introduce the regimens as "advocated by various authorities" and say the dosage "will depend upon the indication", the age and weight of the patient and the physician's preference.1,3

Table 6.1Doses reported in studies and labels7 rows
SourcePeopleDose and routeSchedule and length
Novarel label1Prepubertal cryptorchidism not due to anatomical obstruction14,000, 5,000, 500 to 1,000 or (repeat course) 1,000 USP Units per injection, intramuscular14,000 three times weekly for three weeks; 5,000 every second day for four injections; 15 injections of 500 to 1,000 over six weeks; 500 three times weekly for four to six weeks, and if that course is not successful another begun one month later1
Novarel label; same regimens in the Pregnyl label3Selected cases of hypogonadotropic hypogonadism in males1500 to 1,000 USP Units, or 4,000 USP Units that "may be reduced to 2,000", intramuscular1500 to 1,000 three times a week for three weeks, then twice a week for three weeks; or 4,000 three times weekly for six to nine months, then, if reduced, 2,000 three times weekly for three more months1
Coviello and colleagues, 2005529 healthy men5125, 250 or 500 IU (route not given in the record), with 200 mg testosterone enanthate weekly5Every other day for 3 weeks5
Hsieh and colleagues, 20131126 hypogonadal men on testosterone11500 IU, intramuscular, with testosterone11Every other day; mean follow-up 6.2 months11
Wenker and colleagues, 20151249 men with azoospermia or severe oligospermia on testosterone123,000 units, subcutaneous, with other drugs12Every other day; mean 4.6 months to return of sperm12
Smit and colleagues, 20251319 men using non-prescribed androgens13Recombinant HCG, mean 2,273 IU per week (SD 1,167)13Standard three injections of 520 to 1,040 IU a week; median 17 weeks between sperm analyses13
Rainer and colleagues, 2022628 men with previous exogenous testosterone use, hCG alone61,000 to 2,000 IU per injection (route not given in the sections cited)6Once weekly in 21 men, twice weekly in 6, three times weekly in 16

The Novarel label lists as adverse reactions "Headache, irritability, restlessness, depression, fatigue, edema, precocious puberty, gynecomastia, pain at the site of injection", and reports hypersensitivity reactions that include "erythema, urticaria, rash, angioedema, dyspnea and shortness of breath", adding that "The relationship of these allergic-like events to the polypeptide hormone or the diluent containing benzyl alcohol is not clear".1 Its warnings say that induction of androgen secretion "may induce precocious puberty in patients treated for cryptorchidism", and the Pregnyl label says "in pediatric patients treated for cryptorchidism".1,3 For men the Pregnyl label adds that "Water and sodium retention is occasionally seen after administration of high dosages", regarded as "a result of excessive androgen production", and that "HCG treatment may sporadically cause gynecomastia".3 Both labels state that anaphylaxis has been reported with urinary-derived HCG products.1,3 The Novarel label also notes "sporadic reports of testicular tumors in otherwise healthy young men receiving HCG for secondary infertility", adding that "A causative relationship between HCG and tumor development in these men has not been established".1

In women given HCG with human menopausal gonadotropins, the Novarel label names ovarian hyperstimulation, ovarian cyst enlargement or rupture, multiple births and arterial thromboembolism as principal serious adverse reactions.1

Among the studies cited, Wenker and colleagues report that no man among 49 stopped HCG or the other medicines because of adverse events.12 Rainer and colleagues report that "No VTEs or MACEs were observed" among 28 men followed for a mean of 340.61 ±243.03 days, and list among their limitations a "retrospective design" and "the relatively small sample size of 28".6 One author of that study, Ranjith Ramasamy, declares grants or personal fees from Empower Pharmacy, Acerus Pharmaceuticals, Nestle Health, Boston Scientific, Coloplast, Olympus and Endo Pharmaceuticals, and personal fees from Hims, Inc. (advisory board).6

The app lists total testosterone, free testosterone, estradiol (E2), LH and FSH as markers it associates with HCG, and flags HCG as aromatizing. In the 26 men of Hsieh and colleagues, mean estradiol was 2.2 before and 3.7 pg/ml during testosterone plus 500 IU HCG every other day (p = 0.11; no comparison group).11 In Rainer and colleagues' 28 men, who had stopped exogenous testosterone a mean of 255 days (SD 313; 26 men with data) before starting HCG alone, "no change was seen in FSH, LH, PSA, estradiol, or HbA1c" in the whole cohort, and hematocrit fell from 45.27 ±4.06 to 44.16 ±3.48% (n=15, p<0.05).6 In the 20 men whose baseline labs were taken off testosterone, mean testosterone rose from 307.36 ±148.74 to 422.11 ±268.15 ng/dL (the paper prints n=30 and 31, before and after HCG) and mean PSA fell from 0.91 ±0.35 to 0.69 ±0.23 ng/mL (n=5); in the 8 men whose baseline labs were taken on testosterone, no lab result changed significantly.6

The Novarel label states that "HCG can crossreact in the radioimmunoassay of gonadotropins, especially luteinizing hormone".1

The Novarel and Pregnyl labels both state intramuscular use only.1,3 FDA's consumer update (content current as of 13 July 2020) states that "The FDA has approved HCG as a prescription drug for the treatment of female infertility and for other medical conditions" and that "HCG is not approved for use without a prescription for any purpose. It is not approved for weight loss".16

The Novarel and Pregnyl labels each state in capitals that HCG "has not been demonstrated to be effective adjunctive therapy in the treatment of obesity", and the Novarel label adds, also in capitals, that it "has no known effect on fat mobilization, appetite or sense of hunger, or body fat distribution".1,3

The WADA 2026 Prohibited List names chorionic gonadotrophin (CG) in S2.2.1, "Testosterone-stimulating peptides in males", within class S2, which is prohibited at all times, in and out of competition, and in which all substances are non-Specified Substances.17

10

Storage and handling

The Novarel label states that vials are stored at room temperature, 20° to 25°C, and that, when reconstituted with Bacteriostatic Water for Injection preserved with benzyl alcohol 0.9%, the solution is refrigerated at 2° to 8°C and used within 30 days.1 The Pregnyl label states that the unopened vial is stored at controlled room temperature, 15°C to 25°C, and that reconstituted solution not used immediately is stored refrigerated and discarded after 60 days, adding in capitals "IF NEEDED, THE RECONSTITUTED SOLUTION IS STABLE FOR 60 DAYS WHEN REFRIGERATED" for the solvent packaged with it.3

The Novarel and Pregnyl labels cited give no half-life, bioavailability or time to peak for urinary HCG.1,3

Of the five cited studies in men using or previously using testosterone or androgens, four give HCG together with testosterone or other drugs (Coviello, Hsieh, Smit, Wenker), so they do not report HCG alone on sperm counts; Rainer and colleagues gave HCG alone.6

Rainer and colleagues write that "there is currently scarce data examining the long-term safety of hCG treatment, especially regarding laboratory changes".6

The records of Damewood, Saal, Shah, Rajfer, Lijesen, Coviello, Hsieh, Wenker and Muir give no funding statement or disclosures.2,7,8,9,10,5,11,12,14

What is the half-life of HCG?

The app lists a half-life of about 29 hours for HCG. Damewood and colleagues measured a mean half-life of 2.32 days after intramuscular HCG in 34 patients in an IVF programme, and the Ovidrel label gives about 29 ± 6 hours for subcutaneous recombinant hCG in women.2,4

Is HCG banned by WADA?

Yes, in males: the WADA 2026 Prohibited List names chorionic gonadotrophin (CG) in S2.2.1, testosterone-stimulating peptides in males, in a class prohibited at all times.17

Is HCG approved for weight loss?

No: FDA states that HCG "is not approved for weight loss".16 Lijesen and colleagues concluded in 1995 that "there is no scientific evidence that HCG is effective in the treatment of obesity".10

What is HCG approved for?

The Novarel label lists prepubertal cryptorchidism not due to anatomic obstruction, selected cases of hypogonadotropic hypogonadism in males, and induction of ovulation and pregnancy in certain anovulatory women.1

Does HCG raise testosterone?

The Novarel label states that HCG stimulates the Leydig cells of the testis to produce androgens.1 In 20 men whose baseline labs were taken off testosterone, Rainer and colleagues report mean testosterone rising from 307.36 ±148.74 to 422.11 ±268.15 ng/dL on HCG alone (the paper prints n=30 and 31), while the whole cohort of 28 showed a nonsignificant rise and the 8 men whose baseline labs were taken on testosterone showed no significant change.6

Does HCG affect sperm counts in men using testosterone?

Hsieh and colleagues report that none of 26 men on testosterone replacement plus HCG became azoospermic, in a retrospective review of records.11 Smit and colleagues report that 11 of 19 men using androgens, who were advised to move to a maintenance testosterone ester dose of 125 to 150 mg a week, reached a normal total motile sperm count after HCG, while 6 stayed oligozoospermic and 2 azoospermic, with no control group.13

Does HCG increase estrogen?

In 26 men on testosterone replacement plus 500 IU HCG every other day, mean estradiol was 2.2 pg/ml before and 3.7 pg/ml during treatment (p = 0.11), with no comparison group.11 The Pregnyl label states that "HCG treatment may sporadically cause gynecomastia" in men.3

How long is reconstituted HCG stable?

The Novarel label states 30 days refrigerated after reconstitution with bacteriostatic water preserved with benzyl alcohol 0.9%, and the Pregnyl label states 60 days refrigerated in its "if needed" statement, so the labels differ.1,3

Is HCG given by injection under the skin or into a muscle?

The Novarel and Pregnyl labels state intramuscular use only, and the Ovidrel label for recombinant hCG states subcutaneous use.1,3,4 Saal and colleagues compared both routes in 24 healthy men and report that peak concentration was delayed and half-life prolonged after subcutaneous injection while testosterone, LH and FSH responses were identical, and Shah and colleagues report lower hCG levels after subcutaneous injection in obese women.7,8

What are the side effects of HCG?

The Novarel label lists headache, irritability, restlessness, depression, fatigue, edema, precocious puberty, gynecomastia and pain at the site of injection.1 Both labels state that anaphylaxis has been reported with urinary-derived HCG products.1,3 In women given HCG with menotropins, the Novarel label names ovarian hyperstimulation, enlargement or rupture of ovarian cysts, multiple births and arterial thromboembolism as principal serious reactions, and the Pregnyl label adds bruising, swelling and itching at the injection site.1,3

14

References

  1. Ferring Pharmaceuticals. NOVAREL (chorionic gonadotropin) for injection, for intramuscular use: prescribing information, DailyMed version 41 effective 27 August 2025 (label revised 05/2023). DailyMed. DailyMed Novarel label
  2. Damewood MD, Shen W, Zacur HA, et al. Disappearance of exogenously administered human chorionic gonadotropin. Fertil Steril 1989. PMID 2776893
  3. Organon LLC. PREGNYL (chorionic gonadotropin) for injection: prescribing information, DailyMed version effective 2 December 2025 (label revised 03/2025). DailyMed. DailyMed Pregnyl label
  4. EMD Serono. OVIDREL PreFilled Syringe (choriogonadotropin alfa injection): prescribing information, DailyMed version effective 26 December 2023. DailyMed. DailyMed Ovidrel label
  5. Coviello AD, Matsumoto AM, Bremner WJ, et al. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab 2005. PMID 15713727
  6. Rainer Q, Pai R, Zucker I, et al. The safety of human chorionic gonadotropin monotherapy among men with previous exogenous testosterone use. Cureus 2022. PMC9271319
  7. Saal W, Glowania HJ, Hengst W, Happ J. Pharmacodynamics and pharmacokinetics after subcutaneous and intramuscular injection of human chorionic gonadotropin. Fertil Steril 1991. PMID 1712735
  8. Shah DK, Missmer SA, Correia KF, Ginsburg ES. Pharmacokinetics of human chorionic gonadotropin injection in obese and normal-weight women. J Clin Endocrinol Metab 2014. PMID 24476082
  9. Rajfer J, Handelsman DJ, Swerdloff RS, et al. Hormonal therapy of cryptorchidism. A randomized, double-blind study comparing human chorionic gonadotropin and gonadotropin-releasing hormone. N Engl J Med 1986. PMID 2868413
  10. Lijesen GK, Theeuwen I, Assendelft WJ, Van Der Wal G. The effect of human chorionic gonadotropin (HCG) in the treatment of obesity by means of the Simeons therapy: a criteria-based meta-analysis. Br J Clin Pharmacol 1995. PMID 8527285
  11. Hsieh TC, Pastuszak AW, Hwang K, Lipshultz LI. Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy. J Urol 2013. PMID 23260550
  12. Wenker EP, Dupree JM, Langille GM, et al. The use of HCG-based combination therapy for recovery of spermatogenesis after testosterone use. J Sex Med 2015. PMID 25904023
  13. Smit DL, Verdegaal T, Bond P. Efficacy of human chorionic gonadotropin hormone in restoring spermatogenesis in men using non-prescribed androgens: a retrospective analysis of real-world data. F S Rep 2025. PMC12223563
  14. Muir CA, Zhang T, Jayadev V, Conway AJ, Handelsman DJ. Efficacy of gonadotropin treatment for induction of spermatogenesis in men with pathologic gonadotropin deficiency: a meta-analysis. Clin Endocrinol (Oxf) 2025. PMID 39445789
  15. Panken EJ, Halpern JA. Is combined androgen and gonadotropin therapy a viable harm reduction strategy for men using high-dose exogenous androgens who are interested in family building? F S Rep 2025. PMC12223587
  16. US Food and Drug Administration. Avoid Dangerous HCG Diet Products. Consumer update, content current as of 13 July 2020. FDA consumer update
  17. World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. WADA Prohibited List 2026